Among B-lineage acute lymphoblastic leukaemia (ALL), BCR/ABL1-like ALL is one of the most clinically relevant subsets because it is characterized by a poor outcome and could potentially benefit from the use of tyrosine kinase inhibitor (TKI) therapy (Ofran & Izraeli, 2017) . Mullighan et al (2009a) identified a subgroup of paediatric B-lineage ALL (B-ALL) with a gene expression profile similar to that of BCR/ABL1-positive patients, frequent IKZF1 deletions and poor outcome. Simultaneously, Den Boer et al (2009) performed gene expression profiling (GEP) analysis on a cohort of paediatric B-ALL cases and termed this subgroup BCR/ ABL1-like; it represented 15-20% of B-ALL cases, showed an unfavourable outcome and was associated with IKZF1, TCF3, EBF1, PAX5 and VPREB1 deletions, and upregulation of CRLF2.
Subsequently, the BCR/ABL1-like ALL subgroup has been extensively evaluated, particularly in paediatric cohorts (Mullighan et al, 2009b,c; Harvey et al, 2010a,b; Yoda et al, 2010; Chen et al, 2012; Asai et al, 2013; van der Veer et al, 2013) and more recently in adults (Tokunaga et al, 2013; Boer et al, 2015a; Herold et al, 2017; Jain et al, 2017a; Roberts et al, 2017) . In addition to the association with IKZF1 deletions and CRLF2 deregulation, Roberts et al (2012) unveiled that kinase activating alterations characterize the majority (91%) of paediatric BCR/ABL1-like ALL cases. The most frequent alterations involve ABL1, JAK2, PDGFRB, CRLF2 and EPOR, activating mutations of IL7R, FLT3-internal tandem duplication mutations and deletion of SH2B3 (Roberts et al, , 2014a . Several of these alterations are targeted by TKIs, suggesting a potential role for tailored treatment (Roberts et al, , 2014a . Furthermore, all authors confirmed an association with poor outcome, while the relationship with minimal residual disease (MRD) is still debated (Roberts et al, 2014b; Heatley et al, 2017) .
Despite this in-depth genetic characterization, the identification of BCR/ABL1-like patients is still challenging: it relies on GEP and/or a multistep approach, such as a combination of next generation sequencing (NGS) and fluorescence in situ hybridisation (FISH) (Roberts et al, 2014a) . However, GEP is largely cohort/experiment-dependent and a consensus diagnostic signature has not been agreed upon (Boer et al, 2015b) . Similarly, NGS is costly and requires bioinformatic skills. Alternatively, these cases can be recognized with Low Density Assay (LDA) of selected genes, but the full methodology has not been published (Harvey et al, 2013) . Thus, this study aimed to: (i) produce an easy, rapid and reproducible assay, based on quantitative real time-polymerase chain reaction (Q-RT-PCR) analysis, for the recognition of BCR/ ABL1-like ALL cases; (ii) define the molecular background, clinico-biological features and outcome of the cases thus identified; and (iii) verify the in vitro response of primary BCR/ABL1-like ALL cells to the pan-TKI, ponatinib. The final goal is to provide a rapid, user-friendly and economically-viable diagnostic tool that can recognize these cases at presentation, a step towards a refined prognostic and therapeutic management of these poor prognosis patients.
Methods

Identification of BCR/ABL1-like cases and genes
To identify the core BCR/ABL1-like cases and BCR/ABL1-like specific genes ( Figure S1 ), we used two in house GEP cohorts: GEP1, run on HG-U133 plus2 (Affymetrix, Santa Clara, CA, USA) -comprising 148 B-ALL cases (70 BCR/ ABL1-positive and 78 B-NEG, i.e. negative for BCR/ABL1, ETV6/RUNX1, TCF3/PBX1 and KMT2A rearrangements) (Haferlach et al, 2010; Messina et al, 2010 ) -and GEP2 -including 79 cases (37 BCR/ABL1-positive and 42 B-NEG) (Chiaretti et al, 2005) -evaluated with an older version of the array (HG-U95 Av2, Affymetrix). In both GEP1 and GEP2, a t-test between BCR/ABL1-positive and B-NEG cases was performed to recognize the BCR/ABL1-like ALL cases. B-NEG cases clustering within the BCR/ ABL1-positive cluster were regarded as the "core" BCR/ ABL1-like samples.
To select the BCR/ABL1-like genes ( Figure S2 ), the 16 "core" BCR/ABL1-like ALL cases of GEP1 were compared with the remaining 62 B-NEG cases by t-test. The genes selected by this approach were compared with the literature (Harvey et al, 2010b) and the overlapping genes, together with CRLF2 (Yoda et al, 2010; van der Veer et al, 2013; Chiaretti et al, 2016; Herold et al, 2017) , were used to build the Q-RT-PCR-based BCR/ABL1-like predictor. GEP analyses are detailed in Data S1.
Development and validation of the "BCR/ABL1-like predictor"
To generate the BCR/ABL1-like predictor, we validated the expression levels of the selected genes in the discovery cohort, including 26 core BCR/ABL1-like samples (16 from GEP1 and 10 from GEP2) and 26 non-BCR/ABL1-like selected from GEP1. The quantification of transcript levels was performed by Q-RT-PCR (Data S1 and Table SI) and  computed as 2 ÀDCt .
Q-RT-PCR results were used to build the "BCR/ABL1-like predictor", extensively described in the Data S1. Briefly, expression values were shrunk into principal components (PCs) and a logistic regression model was used to examine the association among the PCs and BCR/ABL1-like ALL cases. Subsequently, a score on PCs was built and used to classify 142 additional B-NEG ALL cases, representing the screening panel.
The analysis of the genetic and clinical features was performed on a total of 194 B-NEG ALL, 52 belonging to the discovery and 142 to the screening panels (Table SII Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) protocols (Table SIII) .
The study was approved by the local IRB, in accordance with the Helsinki Declaration.
Analysis of genetic features
Recurrently mutated JAK/STAT and RAS pathways genes were sequenced in 182/194 samples (Table SIV) . Copy number aberrations (Messina et al, 2017) were assessed by multiplex ligation-dependent probe amplification (MLPA) in 111/194 samples. RNA-sequencing was performed in 54 samples by the TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA). RNA libraries were paired-end sequenced (2 9 100 bp) using the Illumina HiSeq2500 platform. Identification of fusion transcripts was performed by STAR-fusion (STAR-Fusion_v0.5.1) and Fusioncatcher (v0.99.3e) (Nicorici et al, 2014) .
Statistical analysis of clinical features and event-free survival (EFS)
Patients' characteristics were compared by chi-squared or Fisher's exact test for categorical variables and by Wilcoxon test for continuous data. Event-free survival (EFS) and overall survival (OS) was estimated by Kaplan-Meier: EFS was estimated from the time of diagnosis to the occurrence of refractoriness, relapse or death, while OS was estimated from the time of diagnosis to death. Multivariate analysis was performed using the Cox proportional model to adjust the effect of BCR/ABL1-like ALL cases to white blood cell (WBC) count, age and CRLF2 on EFS. All tests were two-sided and P values <0Á05 were considered statistically significant. Analyses were performed using the SAS software (release 9.4; SAS Institute, Cary, NC, USA).
In vitro experiments
To assess the sensitivity to ponatinib, the annexin V/7-aminoactinomycin D (7AAD) apoptotic test (BD Bioscience, San Jos e, CA) and 3 H-thymidine (Perkin Elmer, Waltham, MA) proliferation assays were performed on primary cells from 7 BCR/ABL1-like, 6 non-BCR/ABL1-like and 4 BCR/ABL1-positive cases. Ponatinib (Selleck Chemicals, Houston, TX) at 0 lmol/l (dimethyl sulfoxide only) or at increasing doses (0Á01-10 lmol/l) was added at time 0 and viability was measured after 48 and 72 h (Data S1).
Results
Identification and quantification of BCR/ABL1-like predictor genes in the discovery cohort
The comparison of BCR/ABL1-positive and B-NEG cases of GEP1 (Haferlach et al, 2010; Messina et al, 2010 ) using a t-test recognized 16 B-NEG cases that clustered with the BCR/ABL1-positive cases: these 16 misclustered B-NEG cases were regarded as the "core" BCR/ABL1-like samples ( Figure S2 ). To select the BCR/ABL1-like genes ( Figure S2 ) the "core" BCR/ABL1-like ALL cases were compared with the remaining B-NEG cases by t-test, that resulted in the identification of 285 genes (Table SV) , of which 9 had been previously reported as part of the BCR/ABL1-like signature (Harvey et al, 2010b) . These 9 genes (SOCS2, IFITM1, CD99, TP53INP1, IFITM2, JCHAIN, NUDT4, ADGRE5 and SEMA6A) together with CRLF2 (Yoda et al, 2010; van der Veer et al, 2013; Herold et al, 2017) were used to build the Q-RT-PCR-based BCR/ABL1-like predictor.
By analysing GEP2 (Chiaretti et al, 2005) we selected 10 additional BCR/ABL1-like ALLs, leading to a total of 26 BCR/ABL1-like cases that were included in the discovery panel of this study.
Next, the expression levels of these 10 genes were quantified by Q-RT-PCR in the discovery cohort (n = 52), comprising 26 BCR/ABL1-like and 26 non-BCR/ABL1-like ALLs, classified according to GEP (Chiaretti et al, 2005; Haferlach et al, 2010; Messina et al, 2010) . All genes were significantly overexpressed in BCR/ABL1-like ALL samples ( Figure S3 ).
Development of the "BCR/ABL1-like predictor"
The Q-RT-PCR expression values of the 10 genes were used to build the "BCR/ABL1-like ALL predictor". First, we verified that in univariate analysis, all genes were risk factors for a higher BCR/ABL1-like ALL probability (Table SVI) . As a high correlation was detected among the expression levels of the 10 genes ( Figure S4 ), it was possible to summarize the variability by means of PC analysis; by definition, the PCs thus identified are uncorrelated. In detail, expression values were shrunk into 3 PCs (accounting for >80% of the variability): the contributions of each gene to each component are expressed by factor loadings, a measure of their relationship (Table SVII) . Each component is mainly explained by genes with the highest loadings: PC1 is explained by the expression values of NUDT4, SEMA6A, ADGRE5, SOCS2 and JCHAIN, PC2 by CRLF2, TP53INP1, CD99 and PC3 by IFITM1 and IFITM2.
Second, a logistic regression model was used to estimate the probability of a case being BCR/ABL1-like using the first 3 PCs; all components were statistically significant in multivariate analysis (Table SVIII) .
Finally, to generate a predictive model, a score was computed by means of a linear combination of the PCs, as a result of the above mentioned multivariate logistic regression model. Figure S5 illustrates the generation of the score. The optimal cut-off was set at À0Á30: cases with a score ≥À0Á30 were defined as BCR/ABL1-like. This cut-off provides the best distinction between BCR/ABL1-like and non-BCR/ABL1-like cases and ensures the optimal compromise between sensitivity and specificity (88Á5% and 100%, respectively). The mathematical equation is provided in Data S1.
An online BCR/ABL1-like score calculator was implemented into the web-based application GIMEMA REDCap system hosted at GIMEMA Foundation (Harris et al, 2009 ).
Identification of the BCR/ABL1-like ALL cases and genomic characterization
The predictive model was then validated in a screening cohort of 142 B-NEG ALL patients: 28 cases (19Á7%) were classified as BCR/ABL1-like (min score À0Á279, max score 2Á176) and 114 as non-BCR/ABL1-like ALL (min score À1Á810, max score À0Á353). The comparison of the clinicobiological features of BCR/ABL1-like and non-BCR/ABL1-like ALL cases at diagnosis, carried out in the whole cohort, showed that BCR/ABL1-like ALLs were associated with a significantly higher WBC count at diagnosis (22Á9 vs. 12Á6 9 10 9 /L, P = 0Á013) while no differences were observed for the other parameters (Table I) .
Recurrently mutated genes were investigated in 182/194 cases. Mutations of the JAK/STAT pathway (i.e. JAK1/2, CRLF2 and IL7R) were detected in 44Á2% (23/52) of BCR/ ABL1-like cases and only in 7Á7% (10/130) of the non-BCR/ ABL1-like cases (P < 0Á001), RAS pathway mutations were more frequent in non-BCR/ABL1-like (n = 38/130, 29Á2%) than in BCR/ABL1-like cases (n = 9/52, 17Á3%, P = 0Á068). Details are provided in Table II. We also examined copy number aberrations in 111 cases: IKZF1 deletions were significantly more frequent in BCR/ ABL1-like than non-BCR/ABL1-like cases (82Á8% vs. 40Á8%, P < 0Á001). We found that EBF1 and BTG1 deletions were significantly more frequent in BCR/ABL1-like cases (Table II) .
Finally, CRLF2 levels were significantly higher (P ≤ 0Á001) in BCR/ABL1-like (median DCt = 6Á7, range 0Á6-16Á6) than in non-BCR/ABL1-like cases (median DCt = 11Á3, range 3Á2-17Á9). Complete results are detailed in Tables SIX and SX. Comparable results were obtained when separating the discovery (Table SXI) and screening cohorts (Table III) .
RNA-sequencing, performed in 54 samples (28 BCR/ ABL1-like and 26 non-BCR/ABL1-like), identified 13 fusion transcripts targeting tyrosine kinases (TKs)/cytokine receptors, of which 12 were detected in BCR/ABL1-like cases (12/ 28 vs. 1/26 P = 0Á001). The most recurrent fusion was EBF1/ PDGFRB found in 3 cases; JAK2 rearrangements with different partners (i.e. PAX5, EBF1, SSBP2) were detected in 3 other cases, P2RY8/CRLF2 and TSLP-fusion genes in 2 samples; finally, RCSD1/ABL1 and TRIM24/FGFR1 were found in 1 case each. Within non-BCR/ABL1-like cases, 1 case harboured P2RY8/CRLF2 while no fusion genes targeting TKs were documented. Figure 1 shows that 27/28 (96Á4%) had at least one lesion typical of the BCR/ABL1-like profile and suggests that the BCR/ABL1-like profile is sustained by at least 2 different mechanisms: one represented by TK-rearrangements only and the other by CRLF2 overexpression plus JAK/STAT mutations.
Outcome of the BCR/ABL1-like ALL samples
We analysed the complete remission (CR) rate and survival in the adolescents and adults with clinical data available (n = 142, Table SIII ).
In the whole cohort, the CR rate was lower in BCR/ABL1-like than in non-BCR/ABL1-like cases (77Á8% vs. 89Á6%, P = 0Á06).
Consistently, EFS at 36 months was significantly inferior for BCR/ABL1-like cases compared to non-BCR/ABL1-like cases (21Á6% vs. 47Á2%, P < 0Á0001; Fig 2A) .
When we considered the screening cohort only (n = 95), we confirmed that the CR rate was significantly lower in BCR/ABL1-like than in non-BCR/ABL1-like cases (71Á4% vs. 91Á8%, P = 0Á014). Similarly, EFS at 36 months was significantly inferior for BCR/ABL1-like cases compared to non-BCR/ABL1-like cases (21Á3% vs. 43Á3%, P = 0Á0009; Fig 2B) .
In line with EFS estimates, OS at 36 months was significantly inferior for BCR/ABL1-like cases compared to non-BCR/ABL1-like cases (37Á3% vs. 60Á7%, P = 0Á05; Figure S6A ) in the whole cohort and a similar trend was observed in the screening cohort only ( Figure S6B ). The Table I . Comparison between BCR/ABL1-like and non-BCR/ABL1-like clinico-biological features.
BCR/ABL1-like n = 54
Non-BCR/ABL1-like n = 140 P-value impact of BCR/ABL1-like prediction retained statistical significance on EFS in multivariate analysis (Hazard ratio: 2Á12, 95% confidence interval: 1Á18-3Á82, P = 0Á01) in a model adjusted for age and WBC count. We also evaluated the interaction on EFS between the BCR/ABL1-like signature and CRLF2 overexpression: BCR/ABL1-like prediction retained statistical significance on EFS (P = 0Á05) in the bivariate model adjusted by CRLF2 overexpression.
In vitro sensitivity to ponatinib
After 72 h of incubation with ponatinib (0Á01 lmol/l), a 3 H-thymidine uptake assay showed that the proliferation 
1/26 (3Á8%) P = 0Á001 TSLP-fusions (N = 2) 12/28 (42Á8%) *Three cases carried 2 concomitant JAK/STAT pathway mutations: 2 cases harboured JAK2 and CRLF2 mutations, 1 case harboured IL7R and CRLF2 mutations.
†Two cases carried 2 concomitant RAS pathway mutations: 1 case harboured NRAS and KRAS mutations, 1 case FLT3 and NRAS mutations. ‡Overexpression was defined at DCt < 8 as previously described by Chiaretti et al (2016) . #Correction added on 17 May 2018, after first online publication: The percentage has been corrected from 2064% to 28Á6%. 
ns, not significant. *One case harboured IL7R and CRLF2 mutations.
†One 1 case harboured NRAS and FLT3 mutations.
rate of primary cells from 7 BCR/ABL1-like cases (2 EBF1/ PDGFRB-positive, 1 JAK2-mutated and P2RY8/CRLF2-positive, 1 RCSD1/ABL1, 3 WT for JAK/STAT and RAS mutations) decreased to 33Á6% AE 15%, comparable to the sensitivity observed in 4 BCR-ABL1-positive cases (44Á3-% AE 12Á4%). Contrarily, in the non-BCR-ABL1-like (non-BCR-ABL1-positive) samples (n = 6) -all WT for JAK/ STAT and RAS hotspot mutations -the proliferation rate upon ponatinib treatment decreased only to 71Á5-% AE 28Á7% (P = 0Á0007) (Fig 3A) . Ponatinib (0Á01 lmol/l) also increased the apoptotic rate in both BCR/ABL1-like and BCR/ABL1-positive primary ALL cells (22Á1% AE 10%, 19Á9% AE 8Á5%, respectively), while the apoptotic response in non-BCR/ABL1-like/non-BCR/ABL1-positive ALL was significantly inferior (6Á1% AE 8Á4%, P = 0Á023, Fig 3B) .
Discussion
Although the recognition of the BCR/ABL1-like ALL subset dates back to 2009, a consensus on a BCR/ABL1-like signature has not been reached (Den Boer et al, 2009; Mullighan et al, 2009a ) and a standardized tool to identify these cases is currently not available (Ofran & Izraeli, 2017) . Roberts et al (2014a) and Fasan et al (2015) proposed a combination of different methods: analysis of CRLF2 expression, FISH targeting ABL1 and JAK activating rearrangements, fusion-specific RT-PCR for the identification of the ABL and JAK partners Figure 1 . Distribution of BCR/ABL1-like specific genetic lesions in the samples with a complete molecular characterization. Legend: green boxes for JAK/STAT pathway mutations: wild-type; red boxes: mutation detected. The mutated gene name is provided in the figure; green boxes for RAS pathway mutations: wild-type; red boxes: mutation detected; the mutated gene name is provided in the figure; CRLF2 expression; red boxes: overexpression; TK/cytokine fusions: green boxes: no rearrangement detected; red boxes: rearrangement detected. The fusion gene is specified in the figure; IKZF1 deletions: green boxes: no deletions; blue boxes: presence of deletions; grey boxes: sample not evaluated. Simultaneously, Harvey et al (2013) developed a method based on the quantification of 15 transcripts by LDA and several groups adopted this method (Heatley et al, 2017; Reshmi et al, 2017) . However, the mathematical equations were not provided. Our approach took advantage of previously reported GEP data (Chiaretti et al, 2005; Messina et al, 2010) to identify a narrow list of 10 transcripts (CRLF2, SOCS2, IFITM1, CD99, TP53INP1, IFITM2, JCHAIN, NUDT4, ADGRE5, SEMA6A), capable of accurately identifying the BCR/ABL1-like ALLs.
The genes chosen to build the predictive model are also in common with other algorithms recently used to identify BCR/ABL1-like cases Harvey et al, 2013) .
Using Q-RT-PCR of these 10 transcripts, we built an algorithm capable of identifying BCR/ABL1-like cases with a high sensitivity and specificity. Furthermore, we generated a userfriendly tool, which requires only the upload of gene expression values to assess whether a sample is BCR/ABL1-like or non-BCR/ABL1-like.
Next, the screening of 142 B-NEG ALL samples by the BCR/ABL1-like predictor assigned 28 cases (19Á7%) to the BCR/ABL1-like ALL subset, in line with the reported incidence (Ofran & Izraeli, 2017) .
The prediction accuracy was indirectly corroborated by the analysis of the genetic features of BCR/ABL1-like ALL cases. As reported in both paediatric and adult cohorts, BCR/ ABL1-like ALL is associated with IKZF1 deletions, CRLF2 deregulation/rearrangements, JAK1/2 mutations, rearrangements of genes coding for TKs and cytokine receptors (Mullighan et al, 2009b,c; Harvey et al, 2010a,b; Yoda et al, 2010; Chen et al, 2012; Asai et al, 2013; Tokunaga et al, 2013; van der Veer et al, 2013; Boer et al, 2015a; Ge et al, 2016; Herold et al, 2017; Jain et al, 2017a; Roberts et al, 2017) . Consistently, our BCR/ABL1-like cases frequently carried JAK/STAT pathway mutations, the most recurrent targeting JAK2, followed by CRLF2 and IL7R. In addition, BCR/ABL1-like cases were enriched in IKZF1 deletions, detected in 80% of cases, in line with Herold and colleagues (Herold et al, 2017) .
More importantly, RNA-sequencing -performed in 28 BCR/ABL1-like cases -revealed that 7 carried TK rearrangements, 2 P2RY8/CRLF2 and 2 TSLP-rearrangements. TK-activating fusion genes are specific to BCR/ABL1-like cases and may be targeted by TKIs, as shown in pre-clinical models and sporadic case reports Roberts et al, 2012 Roberts et al, , 2014a Tasian et al, 2012; Lengline et al, 2013; Weston et al, 2013; Shi et al, 2014 Shi et al, , 2015 Francis et al, 2016) .
The integration of all the molecular features, feasible in 28 BCR/ABL1-like, demonstrated that 96Á4% had at least one lesion typical of the BCR/ABL1-like profile and suggested that the BCR/ABL1-like profile is sustained by at least two mechanisms, either a TK-activating fusion or CRLF2 overexpression with a concomitant JAK/STAT mutation; at variance, CRLF2 overexpression alone seems insufficient to induce a BCR/ABL1-like profile.
From a clinical standpoint, the features of the BCR-ABL1-like cases hereby identified were in line with a BCR-ABL1-like profile: they displayed a significantly higher WBC count at diagnosis, a lower CR rate and a significantly worse EFS than non-BCR-ABL1-like patients; we observed no differences related to gender, in agreement with other reports (Boer et al, 2015b; Herold et al, 2017 ). An association with MRD levels was not feasible since this parameter was not available for a large set of patients. Furthermore, the incidence in paediatric cases was lower than in adolescents and adults (9Á5% vs. 29Á5% and 30Á6%, respectively) in our cohort.
Finally, in vitro experiments showed that the pan-TKI, ponatinib, the most potent inhibitor in BCR/ABL1-positive ALL , was able to reduce the proliferative rate in BCR-ABL1-like samples and to increase apoptosis, similarly to that observed in BCR-ABL1-positive ALL. Notably, the BCR-ABL1-like samples analysed by in vitro experiments comprised ABL class lesions, JAK/STAT mutated and WT cases, indicating that ponatinib is active in all cases regardless of the underlying lesion and may represent an alternative to ruxolitinib whose clinical activity remains to be determined (Jain et al, 2017b) . In conclusion, we hereby describe a Q-RT-PCR based assay capable of singling out BCR-ABL1-like patients from the B-NEG ALL cohort. This approach has many advantages: first, it requires minimal amounts of diagnostic RNA; second, it is simple and cost-effective, being based on Q-RT-PCR; third, it is rapid, because the screening can be completed within a few days. This is essential, considering the high rate of refractory cases that -if promptly recognized -could benefit from an alternative approach, contemplating the use of the pan-TKI, ponatinib. These advantages make this tool suitable to be introduced in the diagnostic workflow and appears applicable to many haematology centres, followed by further genomic screens that comprise RNA-sequencing characterization to fully elucidate the underlying molecular lesion in the patients thus identified. Finally, because this assay is not based on a specific target identification, it allows the potential recognition of all BCR/ ABL1-like cases, including those carrying novel genetic lesions. (Sapienza University of Rome) to MM; Finanziamento Medi Progetti Universitari 2015 to SC (Sapienza University of Rome); Fondazione Le Molinette Onlus, Turin (Italy); MM was partly supported by Associazione Cristina Bassi Onlus (Genova). DMW is supported by NCI 5R01CA151898 and 5R01CA17238. SC designed research, analysed data and wrote the manuscript; MM performed experiments, analysed data and wrote the manuscript; SG performed experiments and analysed data; AP designed the BCR/ABL1-like predictor model and performed statistical analyses; ALF, VG, AL, NP performed experiments; FDG performed RNA sequencing experiments; MV performed statistical analyses; MPM, VA, AV and CS provided samples and clinico-biological data; OE and RB analysed RNA-sequencing data; LSL and DW provided clinical samples; GI analysed data and critically revised the manuscript; AG and RF designed the study, analysed data and critically revised the manuscript.
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